Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alba A Brandes

Showing results (141-150 of 178) with videos related to

Pageof 18
Sort By:
Neuro-Oncology|April 28, 2017
Response assessment in medulloblastoma and leptomeningeal seeding tumors: recommendations from the Response Assessment in Pediatric Neuro-Oncology committeeKatherine E Warren, Gilbert Vezina, Tina Y Poussaint, et al.
European Journal of Cancer (Oxford, England : 1990)|June 17, 2019
The added value of health-related quality of life as a prognostic indicator of overall survival and progression-free survival in glioma patients: a meta-analysis based on individual patient data from randomised controlled trialsMarijke Coomans, Linda Dirven, Neil K Aaronson, et al.
Neuro-Oncology|February 20, 2009
Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: A report from EORTC study 26951Mathilde C M Kouwenhoven, Thierry Gorlia, Johan M Kros, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 6, 2016
Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O<sup>6</sup>-Methylguanine-DNA Methyltransferase Biomarker AnalysesTimothy Cloughesy, Gaetano Finocchiaro, Cristóbal Belda-Iniesta, et al.
The Oncologist|September 30, 2018
A Randomized Phase II Trial (TAMIGA) Evaluating the Efficacy and Safety of Continuous Bevacizumab Through Multiple Lines of Treatment for Recurrent GlioblastomaAlba A Brandes, Miguel Gil-Gil, Frank Saran, et al.
Biorxiv : the Preprint Server for Biology|April 2, 2024
Epigenetic landscape reorganization and reactivation of embryonic development genes are associated with malignancy in IDH-mutant astrocytomaSantoesha A Ghisai, Levi van Hijfte, Wies R Vallentgoed, et al.
Neuro-Oncology|November 5, 2019
Symptom clusters in newly diagnosed glioma patients: which symptom clusters are independently associated with functioning and global health status?Marijke B Coomans, Linda Dirven, Neil K Aaronson, et al.
Acta Neuropathologica|October 9, 2024
Epigenetic landscape reorganisation and reactivation of embryonic development genes are associated with malignancy in IDH-mutant astrocytomaSantoesha A Ghisai, Levi van Hijfte, Wies R Vallentgoed, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 20, 2006
Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trialMartin J van den Bent, Antoine F Carpentier, Alba A Brandes, et al.
Neuro-Oncology Practice|December 11, 2020
Measuring change in health-related quality of life: the impact of different analytical methods on the interpretation of treatment effects in glioma patientsMarijke B Coomans, Martin J B Taphoorn, Neil K Aaronson, et al.
Pageof 18

Showing results (141-150 of 178) with videos related to

Sort By:
Pageof 18
Neuro-Oncology|April 28, 2017
Response assessment in medulloblastoma and leptomeningeal seeding tumors: recommendations from the Response Assessment in Pediatric Neuro-Oncology committeeKatherine E Warren, Gilbert Vezina, Tina Y Poussaint, et al.
European Journal of Cancer (Oxford, England : 1990)|June 17, 2019
The added value of health-related quality of life as a prognostic indicator of overall survival and progression-free survival in glioma patients: a meta-analysis based on individual patient data from randomised controlled trialsMarijke Coomans, Linda Dirven, Neil K Aaronson, et al.
Neuro-Oncology|February 20, 2009
Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: A report from EORTC study 26951Mathilde C M Kouwenhoven, Thierry Gorlia, Johan M Kros, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 6, 2016
Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O<sup>6</sup>-Methylguanine-DNA Methyltransferase Biomarker AnalysesTimothy Cloughesy, Gaetano Finocchiaro, Cristóbal Belda-Iniesta, et al.
The Oncologist|September 30, 2018
A Randomized Phase II Trial (TAMIGA) Evaluating the Efficacy and Safety of Continuous Bevacizumab Through Multiple Lines of Treatment for Recurrent GlioblastomaAlba A Brandes, Miguel Gil-Gil, Frank Saran, et al.
Biorxiv : the Preprint Server for Biology|April 2, 2024
Epigenetic landscape reorganization and reactivation of embryonic development genes are associated with malignancy in IDH-mutant astrocytomaSantoesha A Ghisai, Levi van Hijfte, Wies R Vallentgoed, et al.
Neuro-Oncology|November 5, 2019
Symptom clusters in newly diagnosed glioma patients: which symptom clusters are independently associated with functioning and global health status?Marijke B Coomans, Linda Dirven, Neil K Aaronson, et al.
Acta Neuropathologica|October 9, 2024
Epigenetic landscape reorganisation and reactivation of embryonic development genes are associated with malignancy in IDH-mutant astrocytomaSantoesha A Ghisai, Levi van Hijfte, Wies R Vallentgoed, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 20, 2006
Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trialMartin J van den Bent, Antoine F Carpentier, Alba A Brandes, et al.
Neuro-Oncology Practice|December 11, 2020
Measuring change in health-related quality of life: the impact of different analytical methods on the interpretation of treatment effects in glioma patientsMarijke B Coomans, Martin J B Taphoorn, Neil K Aaronson, et al.
Pageof 18